Monday, November 4, 2013

AASLD- Gilead's hepatitis C Sofosbuvir/ledipasvir plus ribavirin or GS-9669

In ELECTRON trial, 100% of hard-to-treat patients cured with sofosbuvir/ledipasvir plus ribavirin or GS-9669

Liz Highleyman
Produced in collaboration with
Published: 04 November 2013

Interferon-free regimens of sofosbuvir and ledipasvir plus either ribavirin or GS-9669 taken for 12 weeks produced sustained response in 100% of treatment-experienced people with genotype 1 chronic hepatitis C virus (HCV) with advanced liver fibrosis or cirrhosis, according to the latest findings from the ELECTRON trial presented yesterday at 'The Liver Meeting 2013', the 64th annual meeting of the American Association for the Study of Liver Diseases (AASLD) in Washington, DC. A related analysis of previously untreated people without cirrhosis found that reducing treatment duration to six weeks led to relapses.

Continue reading.....

No comments:

Post a Comment